RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
-17.44%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$3.87B
AUM Growth
+$3.87B
(-20%)
Cap. Flow
+$304M
Cap. Flow
% of AUM
7.85%
Top 10 Holdings %
Top 10 Hldgs %
45.33%
Holding
116
New
10
Increased
28
Reduced
12
Closed
9
Top Buys
| 1 |
Immunocore
IMCR
|
$79.7M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$59.5M |
| 3 |
argenx
ARGX
|
$40M |
| 4 |
Thermo Fisher Scientific
TMO
|
$34M |
| 5 |
Masimo
MASI
|
$29.2M |
Top Sells
| 1 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$32M |
| 2 |
Globus Medical
GMED
|
$31.5M |
| 3 |
Athira Pharma
ATHA
|
$25.7M |
| 4 |
iTeos Therapeutics
ITOS
|
$15.7M |
| 5 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$14M |
Sector Composition
| 1 | Healthcare | 98.86% |
| 2 | Financials | 0.75% |
| 3 | Industrials | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alnylam Pharmaceuticals
ALNY
$58.5B
| $246M | 6.34% | 1,683,362 | – | – |
|
|
2
Thermo Fisher Scientific
TMO
$186B
| $237M | 6.11% | 435,500 +62,500 | +17% | +$34M |
|
3
Rocket Pharmaceuticals
RCKT
$354M
| $217M | 5.62% | 15,802,802 | – | – |
|
4
PTC Therapeutics
PTCT
$3.92B
| $202M | 5.22% | 5,045,307 -175,921 | -3% | -$7.05M |
|
|
5
Masimo
MASI
$7.59B
| $177M | 4.56% | 1,350,993 +223,400 | +20% | +$29.2M |
|
|
6
argenx
ARGX
$43.6B
| $168M | 4.33% | 442,635 +105,657 | +31% | +$40M |
|
|
7
Immunocore
IMCR
$1.62B
| $149M | 3.85% | 3,996,154 +2,136,683 | +115% | +$79.7M |
|
8
Establishment Labs
ESTA
$1.2B
| $129M | 3.33% | 2,369,138 +50,000 | +2% | +$2.72M |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $126M | 3.27% | 1,882,663 +321,166 | +21% | +$21.6M |
|
10
Illumina
ILMN
$15.8B
| $104M | 2.69% | 564,375 +55,000 | +11% | +$10.1M |
|
11
Cytokinetics
CYTK
$4.23B
| $101M | 2.6% | 2,561,182 | – | – |
|
|
RXDX
12
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $90M | 2.33% | 3,189,605 +431,658 | +16% | +$12.2M |
|
13
Vericel Corp
VCEL
$1.83B
| $88.7M | 2.29% | 3,522,904 -494,666 | -12% | -$12.5M |
|
14
Penumbra
PEN
$10.6B
| $87M | 2.25% | 698,371 +32,500 | +5% | +$4.05M |
|
15
Celldex Therapeutics
CLDX
$1.47B
| $83.2M | 2.15% | 3,084,215 | – | – |
|
16
Ultragenyx Pharmaceutical
RARE
$2.89B
| $81.9M | 2.12% | 1,373,284 | – | – |
|
17
Natera
NTRA
$23.1B
| $75.2M | 1.94% | 2,122,283 +205,000 | +11% | +$7.27M |
|
18
Avidity Biosciences
RNA
$5.99B
| $69.7M | 1.8% | 4,795,000 | – | – |
|
|
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
| $66.9M | 1.73% | 1,179,965 -563,899 | -32% | -$32M |
|
|
CUTR
20
DELISTED
Cutera, Inc.
CUTR
| $66.4M | 1.72% | 1,770,400 +244,137 | +16% | +$9.16M |
|
|
21
Globus Medical
GMED
$8.27B
| $63M | 1.63% | 1,121,527 -560,764 | -33% | -$31.5M |
|
22
PMV Pharmaceuticals
PMVP
$74.2M
| $62.6M | 1.62% | 4,395,677 +523,523 | +14% | +$7.46M |
|
23
Axsome Therapeutics
AXSM
$6.05B
| $62M | 1.6% | 1,618,819 | – | – |
|
|
24
Acadia Pharmaceuticals
ACAD
$4.38B
| $59.5M | 1.54% | +4,224,109 | New | +$59.5M |
|
25
Adicet Bio
ACET
$59.9M
| $57.7M | 1.49% | 3,951,281 +961,799 | +32% | +$14M |
|